European life science venture capital firm Forbion has held the first close of the Growth Opp Fund II – which will invest in late-stage European life sciences funds – at €470 million, according to a report by AltAssets.
The firm is targeting €500 million in total capital commitments for the fund which is expected to reac its hard cap later this summer.
New institutional investors to commit to the fund include the PME and PMT pension funds, plus the Ewing Marion Kauffman Foundation and Reggeborgh, with Pantheon, Wealth Management Partners, and Eli Lilly and Company all reinvesting again.
